AC
EW icon

Apex Capital’s Edwards Lifesciences EW Stock Holding History

Apex Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,590,000
Closed -$18.5M – 65
2013
Q3 		$18.5M Buy
+1,590,000
New +$18.6M 1.32% 34

Other funds holding EW

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FC
Fairpointe Capital Chicago, Illinois $66.3M AUM 101.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Apex Capital's EW Position: Q4 2013 in Review

Apex Capital sold out of Edwards Lifesciences (EW) in Q4 2013, closing a stake of 1,590,000 shares — an estimated $18.5M sold.

Apex Capital first reported a position in EW in Q3 2013 and held it in 1 quarter. The position peaked at $18.5M in Q3 2013. 408 funds tracked by Wall St. Rank hold EW as of Q4 2013.

  • Apex Capital reported no remaining Edwards Lifesciences position as of Q4 2013 after selling out during the quarter.
  • Apex Capital sold 1,590,000 Edwards Lifesciences shares in Q4 2013, an estimated $18.5M.
  • Apex Capital first reported a position in Edwards Lifesciences in Q3 2013 and held it in 1 quarter.
  • Apex Capital's Edwards Lifesciences position peaked at $18.5M in Q3 2013.
  • 408 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2013.

Based on Apex Capital's 13F filing for Q4 2013, filed 4 Feb 2014.